Skip to menu Skip to content Skip to footer
Associate Professor Kate Gartlan
Associate Professor

Kate Gartlan

Email: 

Overview

Background

Dr Kate Gartlan is an immunologist with considerable expertise in cellular immunology, particularly using in vivo models of inflammation to investigate immune-modulation and T cell polarisation. Dr Gartlan began her research career at WEHI within Professor Ken Shortman’s laboratory developing strong skills in both molecular and cell biology, where she became interested in the early factors that influence adaptive immunity. She completed her PhD in 2009 at the Burnet Institute working with Associate Professor Mark Wright, where she studied functional redundancy between Tetraspanin proteins in the immune system. To advance her understanding of inflammatory mediators and adaptive immune polarisation, she moved to the University of Oxford and took up a postdoctoral position within the Sir William Dunn School of Pathology. Working with Professor Quentin Sattentau, she investigated novel ways to modulate T cell polarisation and influence B cell responses to HIV vaccines.

After returning to Australia, she has worked with Professor Geoff Hill at QIMR Berghofer investigating novel therapies to treat graft-versus-host disease (GVHD) in allograft recipients. Dr Gartlan has held active teaching roles within both university and research institute environments, contributing to undergraduate science and medicine programs at both departmental and college levels.

Her main research interests at present surround the role of IL-17 & IL-22 in GVHD, potential therapeutics to modulate T cell polarisation after allogeneic bone marrow/stem cell transplant (BMT/SCT), as well as developing novel inhibitors of graft rejection to improve engraftment after BMT/SCT.

Availability

Associate Professor Kate Gartlan is:
Available for supervision

Works

Search Professor Kate Gartlan’s works on UQ eSpace

53 works between 2006 and 2023

1 - 20 of 53 works

Featured

2019

Journal Article

Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract

Gartlan, Kate H., Koyama, Motoko, Lineburg, Katie E., Chang, Karshing, Ensbey, Kathleen S., Kuns, Rachel D., Henden, Andrea S., Samson, Luke D., Clouston, Andrew D., Lopez, Angel F., MacDonald, Kelli P. A. and Hill, Geoffrey R. (2019). Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. Blood Advances, 3 (19), 2859-2865. doi: 10.1182/bloodadvances.2019000053

Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract

Featured

2019

Journal Article

IL-6 dysregulation originates in dendritic cells and initiates graft-versus-host disease via classical signaling

Wilkinson, Andrew N., Chang, Karshing, Kuns, Rachel D., Henden, Andrea S., Minnie, Simone A., Ensbey, Kathleen S., Clouston, Andrew D., Zhang, Ping, Koyama, Motoko, Hidalgo, Juan, Rose-John, Stefan, Varelias, Antiopi, Vuckovic, Slavica, Gartlan, Kate H. and Hill, Geoffrey R. (2019). IL-6 dysregulation originates in dendritic cells and initiates graft-versus-host disease via classical signaling. Blood, 134 (23), 2092-2106. doi: 10.1182/blood.2019000396

IL-6 dysregulation originates in dendritic cells and initiates graft-versus-host disease via classical signaling

Featured

2017

Journal Article

A critical role for donor-derived IL-22 in cutaneous chronic GVHD

Gartlan, Kate H., Bommiasamy, Hemamalini, Paz, Katelyn, Wilkinson, Andrew N., Owen, Mary, Reichenbach, Dawn K., Banovic, Tatjana, Wehner, Kimberly, Buchanan, Faith, Varelias, Antiopi, Kuns, Rachel D., Chang, Karshing, Fedoriw, Yuri, Shea, Thomas, Coghill, James, Zaiken, Michael, Plank, Maximilian W., Foster, Paul S., Clouston, Andrew D., Blazar, Bruce R., Serody, Jonathan S. and Hill, Geoffrey R. (2017). A critical role for donor-derived IL-22 in cutaneous chronic GVHD. American Journal of Transplantation , 18 (4), 810-820. doi: 10.1111/ajt.14513

A critical role for donor-derived IL-22 in cutaneous chronic GVHD

Featured

2015

Journal Article

Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8<sup>+</sup> T cells that induce GVHD without antileukemic effects

Gartlan, Kate H., Markey, Kate A., Varelias, Antiopi, Bunting, Mark D., Koyama, Motoko, Kuns, Rachel D., Raffelt, Neil C., Olver, Stuart D., Lineburg, Katie E., Cheong, Melody, Teal, Bianca E., Lor, Mary, Comerford, Iain, Teng, Michele W. L., Smyth, Mark J., McCluskey, James, Rossjohn, Jamie, Stockinger, Brigitta, Boyle, Glen M., Lane, Steven W., Clouston, Andrew D., McColl, Shaun R., MacDonald, Kelli P. A. and Hill, Geoffrey R. (2015). Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood, 126 (13), 1609-1620. doi: 10.1182/blood-2015-01-622662

Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8<sup>+</sup> T cells that induce GVHD without antileukemic effects

2023

Conference Publication

Type-1 regulatory T cells are critical for curative immunotherapy outcomes

Zhang, Ping, Gartlan, Kate H., Minnie, Simone A., Yeh, Albert, Takahashi, Shuichiro, Atilla, Erden, Nemychenkov, Nicole S., Boiko, Julie R., Schmidt, Christine R., Legg, Samuel R.W., Sekiguchi, Tomoko, Ensbey, Kathleen S., Koyama, Motoko, Furlan, Scott N. and Hill, Geoffrey R. (2023). Type-1 regulatory T cells are critical for curative immunotherapy outcomes. Immunology 2023™ Meeting, Washington, DC United States, 11-15 May 2023. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.173.11

Type-1 regulatory T cells are critical for curative immunotherapy outcomes

2022

Journal Article

Multiplex microsphere PCR (mmPCR) allows simultaneous gram typing, detection of fungal DNA, and antibiotic resistance genes

Browne, Daniel J., Liang, Fang, Gartlan, Kate H., Harris, Patrick N. A., Hill, Geoffrey R., Corrie, Simon R. and Markey, Kate A. (2022). Multiplex microsphere PCR (mmPCR) allows simultaneous gram typing, detection of fungal DNA, and antibiotic resistance genes. Laboratory Medicine, 53 (5), 459-464. doi: 10.1093/labmed/lmac023

Multiplex microsphere PCR (mmPCR) allows simultaneous gram typing, detection of fungal DNA, and antibiotic resistance genes

2022

Journal Article

Preclinical activity and pharmacokinetic/pharmacodynamic relationship for a series of novel benzenesulfonamide perforin inhibitors

Gartlan, Kate H., Jaiswal, Jagdish K., Bull, Matthew R., Akhlaghi, Hedieh, Sutton, Vivien R., Alexander, Kylie A., Chang, Karshing, Hill, Geoffrey R., Miller, Christian K., O'Connor, Patrick D., Jose, Jiney, Trapani, Joseph A., Charman, Susan A., Spicer, Julie A. and Jamieson, Stephen M. F. (2022). Preclinical activity and pharmacokinetic/pharmacodynamic relationship for a series of novel benzenesulfonamide perforin inhibitors. ACS Pharmacology and Translational Science, 5 (6), 429-439. doi: 10.1021/acsptsci.2c00009

Preclinical activity and pharmacokinetic/pharmacodynamic relationship for a series of novel benzenesulfonamide perforin inhibitors

2021

Journal Article

IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease

Henden, Andrea S., Koyama, Motoko, Robb, Renee J., Forero, Adriana, Kuns, Rachel D., Chang, Karshing, Ensbey, Kathleen S., Varelias, Antiopi, Kazakoff, Stephen H., Waddell, Nicole, Clouston, Andrew D., Giri, Rabina, Begun, Jakob, Blazar, Bruce R., Degli-Esposti, Mariapia A., Kotenko, Sergei V., Lane, Steven W., Bowerman, Kate L., Savan, Ram, Hugenholtz, Philip, Gartlan, Kate H. and Hill, Geoffrey R. (2021). IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 138 (8), 722-737. doi: 10.1182/blood.2020006375

IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease

2021

Journal Article

Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma

Mithraprabhu, Sridurga, Kalff, Anna, Gartlan, Kate H., Savvidou, Ioanna, Khong, Tiffany, Ramachandran, Malarmathy, Cooke, Rachel E., Bowen, Kathryn, Hill, Geoffrey R., Reynolds, John and Spencer, Andrew (2021). Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma. British Journal of Haematology, 193 (1), 160-170. doi: 10.1111/bjh.17080

Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma

2021

Journal Article

A phase 3 double-blind study of the addition of tocilizumab versus placebo to cyclosporin/methotrexate GvHD prophylaxis

Kennedy, Glen, Tey, Siok-Keen, Buizen, Luke, Varelias, Antiopi, Gartlan, Kate H., Curley, Cameron, Olver, Stuart, Chang, Karshing, Butler, Jason, Misra, Ashish, Subramoniapillai, Elango, Morton, Anthony, Durrant, Simon, Henden, Andrea S, Moore, John, Ritchie, David S, Gottlieb, David, Cooney, Julian P, Paul, Sanjoy K and Hill, Geoffrey R. (2021). A phase 3 double-blind study of the addition of tocilizumab versus placebo to cyclosporin/methotrexate GvHD prophylaxis. Blood, 137 (14), 1970-1979. doi: 10.1182/blood.2020009050

A phase 3 double-blind study of the addition of tocilizumab versus placebo to cyclosporin/methotrexate GvHD prophylaxis

2020

Journal Article

ASC modulates CTL cytotoxicity and transplant outcome independent of the inflammasome

Cheong, Melody, Gartlan, Kate H., Lee, Jason S., Tey, Siok-Keen, Zhang, Ping, Kuns, Rachel D., Andoniou, Christopher E., Martins, Jose Paulo, Chang, Karshing, Sutton, Vivien R., Kelly, Greg, Varelias, Antiopi, Vuckovic, Slavica, Markey, Kate A., Boyle, Glen M., Smyth, Mark J., Engwerda, Christian R., MacDonald, Kelli P.A., Trapani, Joseph A., Degli-Esposti, Mariapia A., Koyama, Motoko and Hill, Geoffrey R. (2020). ASC modulates CTL cytotoxicity and transplant outcome independent of the inflammasome. Cancer Immunology Research, 8 (8), 1085-1098. doi: 10.1158/2326-6066.cir-19-0653

ASC modulates CTL cytotoxicity and transplant outcome independent of the inflammasome

2020

Conference Publication

Diverse IL-6 signalling modalities drive pathogenic T cell differentiation and graft-versus-host-disease after allotransplantation

Gartlan, Kate H., Wilkinson, Andrew, Chang, Karshing, Kuns, Rachel D., Henden, Andrea, Minnie, Simone A., Ensbey, Kathleen S., Clouston, Andrew, Zhang, Ping, Koyama, Motoko, Hidalgo, Juan, Rose-John, Stefan, Varelias, Antiopi, Vuckovic, Slavica and Hill, Geoffrey R. (2020). Diverse IL-6 signalling modalities drive pathogenic T cell differentiation and graft-versus-host-disease after allotransplantation. Immunology 2020™ Meeting, Honolulu, HI United States, 8 - 12 May 2020. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.204.supp.87.33

Diverse IL-6 signalling modalities drive pathogenic T cell differentiation and graft-versus-host-disease after allotransplantation

2020

Conference Publication

Posttransplant cyclophosphamide as a platform for immunotherapy after allogeneic stem cell transplantation for multiple myeloma

Minnie, Simone A., Kuns, Rachel D., Ensbey, Kathleen S., Samson, Luke D., Chesi, Marta, Gartlan, Kate H., Smyth, Mark J., Vuckovic, Slavica and Hill, Geoffrey R. (2020). Posttransplant cyclophosphamide as a platform for immunotherapy after allogeneic stem cell transplantation for multiple myeloma. Immunology 2020™ Meeting, Honolulu, HI United States, 8 - 12 May 2020. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.204.supp.87.30

Posttransplant cyclophosphamide as a platform for immunotherapy after allogeneic stem cell transplantation for multiple myeloma

2019

Journal Article

Erratum: Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade(Blood (2018) 132:16 (1675-1688) DOI: 10.1182/blood-2018-01-825240)

Minnie, S. A., Kuns, R. D. and Gartlan, K. H. (2019). Erratum: Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade(Blood (2018) 132:16 (1675-1688) DOI: 10.1182/blood-2018-01-825240). Blood, 134 (21), 1878-1878. doi: 10.1182/blood.2019003727

Erratum: Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade(Blood (2018) 132:16 (1675-1688) DOI: 10.1182/blood-2018-01-825240)

2019

Journal Article

Inhibition of the cytolytic protein perforin prevents rejection of transplanted bone marrow stem cells in vivo

Spicer, Julie A., Miller, Christian K., O'Connor, Patrick D., Jose, Jiney, Giddens, Anna C., Jaiswal, Jagdish K., Jamieson, Stephen M. F., Bull, Matthew R., Denny, William A., Akhlaghi, Hedieh, Trapani, Joseph A., Hill, Geoff R., Chang, Karshing and Gartlan, Kate H. (2019). Inhibition of the cytolytic protein perforin prevents rejection of transplanted bone marrow stem cells in vivo. Journal of Medicinal Chemistry, 63 (5) acs.jmedchem.9b00881, 2229-2239. doi: 10.1021/acs.jmedchem.9b00881

Inhibition of the cytolytic protein perforin prevents rejection of transplanted bone marrow stem cells in vivo

2019

Journal Article

Imaging flow cytometry to assess antigen-presenting-cell function

Markey, Kate A. and Gartlan, Kate H. (2019). Imaging flow cytometry to assess antigen-presenting-cell function. Current Protocols in Immunology, 125 (1) e72. doi: 10.1002/cpim.72

Imaging flow cytometry to assess antigen-presenting-cell function

2019

Journal Article

Expansion of IL-17A-secreting CD8 + mucosa-associated invariant T cells in peripheral blood following stem cell mobilization

Varelias, Antiopi, Gartlan, Kate H., Wilkinson, Andrew N., Olver, Stuart D., Samson, Luke D., Tey, Siok-Keen, MacDonald, Kelli P. A. and Hill, Geoffrey R. (2019). Expansion of IL-17A-secreting CD8 + mucosa-associated invariant T cells in peripheral blood following stem cell mobilization. Blood Advances, 3 (5), 718-723. doi: 10.1182/bloodadvances.2018025601

Expansion of IL-17A-secreting CD8 + mucosa-associated invariant T cells in peripheral blood following stem cell mobilization

2019

Journal Article

Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells

Zhang, Ping, Raju, Jyothy, Ullah, Md Ashik, Au, Raymond, Varelias, Antiopi, Gartlan, Kate H, Olver, Stuart D., Samson, Luke D., Sturgeon, Elise, Zomerdijk, Nienke, Avery, Judy, Gargett, Tessa, Brown, Michael P., Coin, Lachlan J., Ganesamoorthy, Devika, Hutchins, Cheryl, Pratt, Gary R, Kennedy, Glen A., Morton, A. James, Curley, Cameron I., Hill, Geoffrey R. and Tey, Siok-Keen (2019). Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells. Clinical Cancer Research, 25 (6), 1749-1755. doi: 10.1158/1078-0432.CCR-18-3069

Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells

2018

Journal Article

Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis

Welz, M., Eickhoff, S., Abdullah, Z., Trebicka, J., Gartlan, K. H., Spicer, J. A., Demetris, A. J., Akhlaghi, H., Anton, M., Manske, K., Zehn, D., Nieswandt, B., Kurts, C., Trapani, J. A., Knolle, P., Wohlleber, D. and Kastenmüller, W. (2018). Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. Nature Communications, 9 (1) 4805, 4805. doi: 10.1038/s41467-018-07213-x

Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis

2018

Journal Article

Myeloma escape after stem cell transplantation is a consequence of t-cell exhaustion and is prevented by tigit blockade

Minnie, Simone A., Kuns, Rachel D., Gartlan, Kate H., Zhang, Ping, Wilkinson, Andrew N., Samson, Luke, Guillerey, Camille, Engwerda, Christian, MacDonald, Kelli P. A., Smyth, Mark J., Markey, Kate A., Vuckovic, Slavica and Hill, Geoffrey R. (2018). Myeloma escape after stem cell transplantation is a consequence of t-cell exhaustion and is prevented by tigit blockade. Blood, 132 (16), 1675-1688. doi: 10.1182/blood-2018-01-825240

Myeloma escape after stem cell transplantation is a consequence of t-cell exhaustion and is prevented by tigit blockade

Supervision

Availability

Associate Professor Kate Gartlan is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • What is the influence of infection driven T cell polarisation on graft-versus-host disease?

    Background: Stem cell/bone marrow transplantation (SCT/BMT) is an important curative therapy for haematological malignancies and disorders; however graft-versus-host disease (GVHD) and infection are two major complications of this procedure. Whilst it is well established that viral and bacterial infections influence GVHD pathogenesis, the impact of fungal infection after transplant is poorly understood. In non-transplant settings, adaptive immune responses to fungal infections are commonly associated with IL-17 production by T cells that enhance anti-fungal immunity. However our laboratory and others have demonstrated that the IL-17 differentiation pathway is pathogenic in the context of allotransplantation. We are offering a project designed to understand the relationship between fungal infection and GVHD outcomes.

    Aims: This project aims to 1) establish an in vivo infection model that can be used in conjunction with bone marrow transplant in pre-clinical experimental systems. 2) Explore the relationship between fungal infection, T cell polarisation and GVHD.

    Significance: Once established, this model will be the first of its kind and will be an important tool to examine the influence of infection on inflammatory diseases.

    Suitability: This project would suit a PhD student.

    Supervisors: Dr Kate Gartlan (Kate.Gartlan@qimrberghofer.edu.au) and Prof Geoff Hill (Geoff.Hill@qimrberghofer.edu.au)

  • Modulating donor T cell polarisation after bone marrow transplantation to prevent graft-versus-host disease

    Background: Stem cell transplantation (SCT) is an effective cancer treatment, however its application is limited by graft-versus-host disease (GVHD), which has a major impact on patient morbidity and mortality. Unfortunately, GVHD severity and tumour clearance are positively correlated and therefore new therapies designed to reduce GVHD must be targeted, such that anti-tumour immunity is maintained. Donor T cell polarization is a critical factor influencing the severity and tissue distribution of graft-versus-host disease (GVHD) and the potency of graft-versus-leukaemia (GVL) effects after allo-SCT. We have identified a pathogenic donor T cell differentiation program that exacerbates GVHD without contributing to tumour clearance, which is characterised by a unique transcription factor expression profile.

    Aims: This study will 1) examine T cell transcription factor expression after allo-SCT in both murine and clinical samples, and 2) utilise a small molecule inhibitor that modulates transcription factor expression to assess its therapeutic potential in the context of GVHD.

    Significance: This therapeutic approach is highly novel and will provide the first essential proof-of-concept data to support small molecule modulation of T cell polarisation as a method for GVHD prevention and treatment.

    Suitability: This project would suit either Honours or PhD students.

    Supervisors: Dr Kate Gartlan (Kate.Gartlan@qimrberghofer.edu.au) and Prof Geoff Hill (Geoff.Hill@qimrberghofer.edu.au)

  • Characterising miRNA expression after bone marrow transplantation to develop novel therapeutics

    Background: Micro RNAs (miRNAs) are small RNA molecules (~25 nucleotides) known to play an important role in regulating inflammation. Therefore miRNA may be a novel target to treat inflammatory diseases such as graft-versus-host disease (GVHD). GVHD develops in >50% of leukaemia patients that receive a donor stem cell/bone marrow transplant (SCT/BMT). GVHD has a major impact on the mortality and quality-of-life for these cancer survivors, however treatment options are very limited and steroid refractory GVHD patients (~20%) have particularly high mortality rates. Unfortunately, GVHD severity and tumour clearance are positively correlated, which means a balance must be struck between providing anti-tumour immunity and reducing the risks associated with GVHD. Our laboratory is therefore investigating novel therapeutics such as miRNAs to modulate inflammatory responses after BMT/SCT.

    Aims: We are currently offering a project designed to 1) characterise miRNA expression profiles in patient serum after BMT/SCT and 2) to evaluate potential inflammatory biomarkers of GVHD.

    Significance: New therapies are urgently needed to minimise the effects of GVHD after donor SCT/BMT. This project will use molecular and cell biology techniques and clinical samples to identify potential new targets for GVHD immunotherapy.

    Suitability: This project would suit either Honours or PhD students.

    Supervisors: Dr Kate Gartlan (Kate.Gartlan@qimrberghofer.edu.au) and Prof Geoff Hill (Geoff.Hill@qimrberghofer.edu.au)

Supervision history

Current supervision

  • Doctor Philosophy

    Modulating Donor T Cell Polarisation After Bone Marrow Transplantation to Prevent Graft-Versus-Host Disease

    Principal Advisor

    Other advisors: Dr Antiopi Varelias

Completed supervision

Media

Enquiries

For media enquiries about Associate Professor Kate Gartlan's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au